Literature DB >> 18837770

Extreme hyperglycemia with ketoacidosis and hyperkalemia in a patient on chronic hemodialysis.

Arvin Gupta1, Mark Rohrscheib, Antonios H Tzamaloukas.   

Abstract

A patient on hemodialysis for end-stage renal disease secondary to diabetic nephropathy was admitted in a coma with Kussmaul breathing and hypertension (232/124 mmHg). She had extreme hyperglycemia (1884 mg/dL), acidosis (total CO(2) 4 mmol/L), hyperkalemia (7.2 mmol/L) with electrocardiographic abnormalities, and hypertonicity (330.7 mOsm/kg). Initial treatment with insulin drip resulted in a decrease in serum potassium to 5.3 mmol/L, but no significant change in mental status or other laboratory parameters. Hemodialysis of 1.75 hours resulted in rapid decline in serum glucose and tonicity and rapid improvement of the acidosis, but no change in mental status, which began to improve slowly after the hemodialysis was stopped, but with ongoing treatment with continuous insulin infusion. The rate of decline in tonicity during hemodialysis (14.5 mOsm/kg/h) was high, raising concerns about neurological complications. In this case, extreme hyperglycemia with ketoacidosis, hyperkalemia, and coma developing in a hemodialysis patient responded to insulin infusion. Monitoring of the clinical status and the pertinent laboratory values is required to assess the need for other therapeutic measures including volume and potassium replacement and emergency dialysis. The indications for and risks of emergency dialysis in this setting are not clearly defined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837770     DOI: 10.1111/j.1542-4758.2008.00324.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  7 in total

Review 1.  Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: review of published reports.

Authors:  Antonios H Tzamaloukas; Todd S Ing; Moses S Elisaf; Dominic S C Raj; Kostas C Siamopoulos; Mark Rohrscheib; Glen H Murata
Journal:  Int Urol Nephrol       Date:  2010-09-09       Impact factor: 2.370

Review 2.  Respiratory failure in diabetic ketoacidosis.

Authors:  Nikifor K Konstantinov; Mark Rohrscheib; Emmanuel I Agaba; Richard I Dorin; Glen H Murata; Antonios H Tzamaloukas
Journal:  World J Diabetes       Date:  2015-07-25

Review 3.  Dialysis-associated hyperglycemia: manifestations and treatment.

Authors:  Yijuan Sun; Maria-Eleni Roumelioti; Kavitha Ganta; Robert H Glew; James Gibb; Darlene Vigil; Catherine Do; Karen S Servilla; Brent Wagner; Jonathan Owen; Mark Rohrscheib; Richard I Dorin; Glen H Murata; Antonios H Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2020-01-18       Impact factor: 2.370

4.  The Capacity to Secrete Insulin Is Dose-Dependent to Extremely High Glucose Concentrations: A Key Role for Adenylyl Cyclase.

Authors:  Katherine M Gerber; Nicholas B Whitticar; Daniel R Rochester; Kathryn L Corbin; William J Koch; Craig S Nunemaker
Journal:  Metabolites       Date:  2021-06-19

5.  End-Stage Renal Disease Increases Rates of Adverse Glucose Events When Treating Diabetic Ketoacidosis or Hyperosmolar Hyperglycemic State.

Authors:  Caitlin M Schaapveld-Davis; Ana L Negrete; Joanna Q Hudson; Jagannath Saikumar; Christopher K Finch; Mehmet Kocak; Pan Hu; Megan A Van Berkel
Journal:  Clin Diabetes       Date:  2017-10

6.  The Corrected Serum Sodium Concentration in Hyperglycemic Crises: Computation and Clinical Applications.

Authors:  Todd S Ing; Kavitha Ganta; Gautam Bhave; Susie Q Lew; Emmanuel I Agaba; Christos Argyropoulos; Antonios H Tzamaloukas
Journal:  Front Med (Lausanne)       Date:  2020-08-25

Review 7.  Serum Sodium Concentration and Tonicity in Hyperglycemic Crises: Major Influences and Treatment Implications.

Authors:  Antonios H Tzamaloukas; Zeid J Khitan; Robert H Glew; Maria-Eleni Roumelioti; Helbert Rondon-Berrios; Moses S Elisaf; Dominic S Raj; Jonathan Owen; Yijuan Sun; Kostas C Siamopoulos; Mark Rohrscheib; Todd S Ing; Glen H Murata; Joseph I Shapiro; Deepak Malhotra
Journal:  J Am Heart Assoc       Date:  2019-09-24       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.